Supernus Deal History & Licensing Activity
Supernus is a biotech headquartered in Israel. The company currently has 10 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
3
Active Trials
10
Top Modality
N/A
Focus Area
CNS Disorders
Supernus Pipeline Focus
Therapeutic areas and modalities where Supernus is most active based on deal history and clinical trial data.
Therapeutic Areas
Supernus Strategic Signals
Key indicators of Supernus's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Supernus Clinical Pipeline
Supernus has 10 active clinical trials across 5 development phases.
2
Unknown
1
Phase 4
1
Phase 1
4
Phase 2
2
Phase 3
See How Your Asset Matches Supernus's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
About Supernus Licensing & Deal Activity
Supernus is a biotech company based in Israel that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for Supernus include CNS Disorders (6 deals and trials).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Supernus and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Supernus's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.